Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Danaher's (DHR) healthy businesses are likely to aid, driven by segmental performances in the first quarter of 2020. However, concerns related to the coronavirus outbreak persist.

Healthy Business to Aid Danaher in Q1 Despite Coronavirus Woes

Danaher (DHR) provides an update on first-quarter 2020 results and withdraws its earlier announced guidance for 2020 on the impacts of the coronavirus outbreak.

Danaher Gives Update on Q1 Results, Withdraws 2020 Guidance

Danaher Corp. DHR, +0.41% said Monday it expects revenue growth of about 3% for the quarter ended April 3.

Danaher sees April quarter revenue growth of about 3%, withdraws 2020 guidance

PPG Industries

Xylem

Danaher, PPG Industries, and Xylem will give a nice balance to your portfolio.

3 Stocks to Build Your Portfolio Around: GHR, PPG & XYL

Danaher stock has come under pressure like many others.  But this is really an opportunity.

Here’s What Makes Danaher Stock a Safe Haven During the Pandemic

Danaher (DHR) prices euro 750 million worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.

Danaher (DHR) Prices Senior Notes Offering Worth Euro 750M

Danaher stock has pulled back too far, opening up a long-term value opportunity. Meanwhile, its Cepheid business can help tackle Covid-19.

Danaher Stock Still Offers Investors the Best of Both Worlds

General Electric

Danaher (DHR) completes the acquisition of General Electric's BioPharma business. The buyout will likely strengthen the company's biologics workflow solutions business.

Danaher Closes Buyout of General Electric's BioPharma Business

General Electric (GE) completes the divestment of its BioPharma business to Danaher. The net proceeds received from the transaction will be used by General Electric to lower its debt burden.

General Electric Closes Divestment of BioPharma to Danaher

Danaher is paying over $21 billion for the business, which will be renamed Cytiva.

General Electric Sale of Biopharma Unit to Danaher Closes

Abbott Labs

The U.S. and Germany recently set new dates to examine reopening their economies, and an exciting new test could speed the process along.

New Shutdown Repeal Dates and a Testing Breakthrough Could Be Game-Changers for the Market

Danaher (DHR) prices euro 1.75 billion worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.

Danaher (DHR) Prices Euro 1.75B Worth Senior Notes Offering

Ford Motor Company

Honeywell

Several industrial conglomerates including General Electric (GE), Honeywell (HON), Danaher (DHR) and 3M (MMM) are increasing steps to mitigate the effects of the coronavirus menace.

Conglomerates Accelerate Efforts to Fight Coronavirus Menace

Late Friday night, the U.S. Food And Drug Administration approved the first coronavirus test that can be conducted entirely at the point of care for a patient and deliver results in 45 minutes.

Danaher's Cepheid Receives FDA Emergency Use Authorization For 45-Minute Coronavirus Test

The FDA has approved the first coronavirus test that quickly provides results on site.

Early FDA Approval to Speed Up Coronavirus Testing

This $20 billion transaction is expected to close on March 31.

GE and Danaher Get FTC Clearance for BioPharma Deal

Danaher (DHR) receives a go-ahead for the acquisition of GE's BioPharma business. The buyout will likely strengthen its biologics workflow solutions business.

Danaher to Soon Close BioPharma Buyout, Receives FTC Approval

Crown Castle International

NVIDIA

After a day of almost normal trading on Thursday, Friday's big stock charts take the temperature of a few large-cap names.
The post 3 Big Stock Charts for Friday: Nvidia, Danaher, and Crown Castle appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Nvidia, Danaher, and Crown Castle

Danaher (DHR) to gain from synergistic benefits from acquired assets as well as innovation efforts and shareholder-friendly policies. High costs and debts along with forex woes might be dragging.

Danaher (DHR) Poised to Gain From Buyouts Despite Cost Woes

The healthcare-focused company's stock got taken down with the rest of the market, but is the market being rational?

Why Danaher Stock Crashed in February

February Performance Of The Concentrated High Growth Dividend Portfolio

Buy Danaher For Total Return With Earnings Beat In Last Quarter

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Why Is Danaher (DHR) Down 14.5% Since Last Earnings Report?

Ball

Kimberly-Clark

Mastercard

McCormick

Target

Waste Management

These blue-chip stocks to buy represent stable industries, reliable dividends and big growth potential. These are all long-term buys.

7 Smart Blue-Chip Stocks to Buy Now

Danaher Corporation (DHR) CEO Tom Joyce on Q4 2019 Results - Earnings Call Transcript

News for Danaher Stock (DHR)